Pratley RE - Search Results

1

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).

Pratley RE, Emerson SS, Franek E, Gilbert MP, Marso SP, McGuire DK, Pieber TR, Zinman B, Hansen CT, Hansen MV, Mark T, Moses AC, Buse JB; DEVOTE Study Group. Pratley RE, et al. Diabetes Obes Metab. 2019 Jul;21(7):1625-1633. doi: 10.1111/dom.13699. Epub 2019 Apr 15. Diabetes Obes Metab. 2019. PMID: 30850995 Free PMC article. Clinical Trial.

2

Impaired fasting glucose and impaired glucose tolerance: implications for care.

Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B; American Diabetes Association. Nathan DM, et al. Diabetes Care. 2007 Mar;30(3):753-9. doi: 10.2337/dc07-9920. Diabetes Care. 2007. PMID: 17327355 Review. No abstract available.

3

Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy.

Pratley RE, Rosenstock J, Pi-Sunyer FX, Banerji MA, Schweizer A, Couturier A, Dejager S. Pratley RE, et al. Diabetes Care. 2007 Dec;30(12):3017-22. doi: 10.2337/dc07-1188. Epub 2007 Sep 18. Diabetes Care. 2007. PMID: 17878242 Clinical Trial.

4

The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?

Singaram V, Pratley R. Singaram V, et al. Diab Vasc Dis Res. 2007 Sep;4(3):237-40. doi: 10.3132/dvdr.2007.047. Diab Vasc Dis Res. 2007. PMID: 17907116 Free article. Review.

5

Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database.

Pratley RE, Schweizer A, Rosenstock J, Foley JE, Banerji MA, Pi-Sunyer FX, Mills D, Dejager S. Pratley RE, et al. Diabetes Obes Metab. 2008 Sep;10(10):931-8. doi: 10.1111/j.1463-1326.2007.00835.x. Epub 2007 Dec 17. Diabetes Obes Metab. 2008. PMID: 18093207

6

LAP-BAND or medical therapy for metabolic syndrome?

Gilbert M, Pratley RE. Gilbert M, et al. Among authors: pratley re. Curr Diab Rep. 2008 Feb;8(1):5-6. doi: 10.1007/s11892-008-0002-5. Curr Diab Rep. 2008. PMID: 18366991 No abstract available.

7

Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.

Pratley RE, Gilbert M. Pratley RE, et al. Rev Diabet Stud. 2008 Summer;5(2):73-94. doi: 10.1900/RDS.2008.5.73. Epub 2008 Aug 10. Rev Diabet Stud. 2008. PMID: 18795210 Free PMC article.

8

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.

Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q; Alogliptin Study 007 Group. Pratley RE, et al. Diabetes Obes Metab. 2009 Feb;11(2):167-76. doi: 10.1111/j.1463-1326.2008.01016.x. Diabetes Obes Metab. 2009. PMID: 19125778 Clinical Trial.

9

Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.

Gilbert MP, Pratley RE. Gilbert MP, et al. Among authors: pratley re. Am J Med. 2009 Jun;122(6 Suppl):S11-24. doi: 10.1016/j.amjmed.2009.03.013. Am J Med. 2009. PMID: 19464424 Review.

10

Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.

Gilbert MP, Pratley RE. Gilbert MP, et al. Among authors: pratley re. Eur J Intern Med. 2009 Jul;20 Suppl 2:S309-18. doi: 10.1016/j.ejim.2009.05.011. Epub 2009 Jun 21. Eur J Intern Med. 2009. PMID: 19580950 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

442 results

Search Page

Filters